Market Executive Summary

The global market for Immuno-oncology Drugs was estimated to be worth US$ 23570 million in 2024 and is forecast to a readjusted size of US$ 68690 million by 2031 with a CAGR of 16.8% during the forecast period 2025-2031.

Immunotherapy is treatment that uses a certain part of a person’s immune system to fight diseases which is done by stimulating one’s own immune system to work harder to attack cancer cells or by giving immune system components, such as man-made immune system proteins. Immunotherapy includes treatments that work in different ways. Some boost the body’s immune system in a very general way and others help train the immune system to attack cancer cells specifically.

The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs.

However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.

This report aims to provide a comprehensive presentation of the global market for Immuno-oncology Drugs, focusing on the total sales revenue, key companies market share and ranking, together with an analysis of Immuno-oncology Drugs by region & country, by Type, and by Application.

The Immuno-oncology Drugs market size, estimations, and forecasts are provided in terms of sales revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. With both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Immuno-oncology Drugs.

Global Immuno-oncology Drugs Companies Covered

Amgen, Inc, AstraZeneca, Plc, Bristol-Myers Squibb, Celgene Corporation, Eli Lilly and Company, Merck & Co., Hoffmann-La Roche AG, Johnson & Johnson, Novartis International AG, AbbVie, Inc., Pfizer Inc., Sanofi S.A., EMD Serono, Inc., Gilead Sciences Inc., Prometheus Therapeutics & Diagnostics, Aduro BioTech, Galena Biopharma, Bavarian Nordic, Celldex Therapeutics, ImmunoCellular Therapeutics, Incyte, Dendreon Corporation, Agilent Technologies Inc., Agenus Inc., Enzo Biochem, Inc., Lonza Group, Bio-Rad Laboratories, Inc., Avantor, Inc., Spring Bank Pharmaceuticals, Inc., Ferring Pharmaceuticals

Global Immuno-oncology Drugs Market, by Region

North America (U.S., Canada, Mexico)

Europe (Germany, France, UK, Italy, etc.)

Asia Pacific (China, Japan, South Korea, Southeast Asia, India, etc.)

South America (Brazil, etc.)

Middle East and Africa (Turkey, GCC Countries, Africa, etc.)

Global Immuno-oncology Drugs Market, Segment by Type

Immune Checkpoint Inhibitors

Immune System Modulators

Cancer Vaccines

Oncolytic Virus

Others

Global Immuno-oncology Drugs Market, Segment by Application

Hospitals

Clinics

Ambulatory Surgical Centers

Chapter Outline

Chapter 1: Introduces the report scope of the report, global total market size. This chapter also provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 2: Detailed analysis of Immuno-oncology Drugs company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 3: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 4: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 5: Revenue of Immuno-oncology Drugs in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 6: Revenue of Immuno-oncology Drugs in country level. It provides sigmate data by Type, and by Application for each country/region.

Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product revenue, gross margin, product introduction, recent development, etc.

Chapter 8: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 9: Conclusion.

Related Reports:

Global Real World Evidence Solutions for Oncology Market Size, Growth Drivers, Share, Key Players, Competitive Analysis, Trends, Opportunities, Revenue Insights, and Demand Forecast to 2032

South Korea Oncology Drugs Market Size, Share, Growth Drivers, Trends, Competitive Analysis, and Forecast to 2030